Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

This grant supports development and validation of animal models and ex vivo model systems, with matched controls when needed, for neurological or neuromuscular diseases, including new endpoints or readouts that better reflect human disease. It uses a two-phase R61/R33 award: the R61 covers initial development, optimization, and internal validation, and the R33 covers scaling, external validation, and independent replication. Eligible applicants include a wide range of U.S. and non-U.S. organizations, including nonprofits, universities, for-profit organizations, small businesses, governments, and foreign organizations. Direct costs cannot exceed $499,000 in any one year and $750,000 total over three years, and no cost sharing is required. Clinical trials are not allowed, and small business applicants are encouraged to use SBIR or STTR opportunities.

✳ AI-generated summary — verify against the announcement

• Health
• Research & Discovery
• Researchers & Scholars
• Biomedical & Disease Research

• ✓ City or township governments
• ✓ County governments
• ✓ For-profit organizations other than small businesses
• ✓ Independent school districts
• ✓ Native American tribal governments (Federally recognized)
• ✓ Native American tribal organizations (other than Federally recognized)
• ✓ Nonprofits with 501(c)(3) status (other than higher education)
• ✓ Nonprofits without 501(c)(3) status (other than higher education)
• ✓ Others
• ✓ Private institutions of higher education
• ✓ Public and State controlled institutions of higher education
• ✓ Public housing authorities / Indian housing authorities
• ✓ Small businesses
• ✓ Special district governments
• ✓ State governments